Is Gilead Sciences a Buy After Its Disappointing Q2 Results?

Is Gilead Sciences a Buy After Its Disappointing Q2 Results?

Gilead Sciences (NASDAQ: GILD) beat Wall Street estimates when the big biotech announced its first-quarter results in late April. Last week, Gilead announced second-quarter results that were below analysts' expectations. Gilead has been in the news quite a bit in recent months thanks to the clinical success for its COVID-19 therapy remdesivir.